Skip to main content
. 2021 Aug 4;26(10):e1822–e1832. doi: 10.1002/onco.13900

Table 2.

Treatment characteristics and clinical features of pneumonitis

Characteristics RT alone ICI alone RT + ICI p value
Number of patients 29 23 30
Thoracic RTa
Prescription dose (Gy) 61.2 (45–72) NA 63 (52.5–66.6) .57
Lung V20 (% total lung) 28 (17–41) NA 24 (14–37) .03
Mean lung dose (Gy) 16.1 (9.6–21.7) NA 13.5 (8.6–18.9) .02
ICI type (%) NA .01
Nivolumab NA 16 (70) 13 (43)
Pembrolizumab NA 3 (13) 3 (10)
Ipilimumab‐Nivolumab NA 4 (17) 3 (10)
Durvalumab NA 0 11 (37)
Interval between RT and ICI, mo NA NA 4.5 (0.4–48.1) NA
Other treatments, n (%)
Chemotherapy 15 (65) 28 (97) 29 (97) .001
Thoracic surgery 4 (17) 8 (28) 6 (20) .67
Time to pneumonitis onset, moa 3.1 (0.4–12.0) 2.7 (0.1–17.5) 1.2 (0.1–34.3) .12
Pneumonitis grade (%) .59
1 0 2 (9) 1 (3)
2 19 (66) 12 (52) 19 (63)
3 9 (31) 6 (26) 7 (23)
4 1 (3) 3 (13) 3 (10)
a

Continuous variables are presented as median (range).

Abbreviations: ICI, immune checkpoint inhibitor; RT, radiotherapy; V20, volume of the lung receiving 20 Gy or higher.